J I Friedman

Summary

Country: USA

Publications

  1. ncbi Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls
    Cheuk Y Tang
    Department of Radiology, Mount Sinai School of Medicine NY, NY 10029, USA
    BMC Psychiatry 7:25. 2007
  2. ncbi Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neuropsychopharmacology 36:1289-95. 2011
  3. ncbi Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Psychopharmacology (Berl) 174:45-53. 2004
  4. ncbi Potential noradrenergic targets for cognitive enhancement in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    CNS Spectr 9:350-5. 2004
  5. ncbi Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 159:1388-94. 2002
  6. ncbi A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychopharmacol 28:59-63. 2008
  7. ncbi Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients
    Joseph I Friedman
    Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:1024-32. 2008
  8. ncbi The effects of hypertension and body mass index on cognition in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 167:1232-9. 2010
  9. ncbi Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging
    J I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Am J Psychiatry 158:1441-8. 2001
  10. ncbi The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychopharmacol 25:237-42. 2005

Research Grants

  1. Pimozide Augmentation of Clozapine in Schizophrenia
    Joseph Friedman; Fiscal Year: 2007

Detail Information

Publications24

  1. ncbi Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls
    Cheuk Y Tang
    Department of Radiology, Mount Sinai School of Medicine NY, NY 10029, USA
    BMC Psychiatry 7:25. 2007
    ..DTI is thus sensitive to demyelination and other structural abnormalities. DTI has also shown abnormalities in these regions...
  2. ncbi Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neuropsychopharmacology 36:1289-95. 2011
    ..However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted...
  3. ncbi Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Psychopharmacology (Berl) 174:45-53. 2004
    ..Therefore, pharmacological treatments that enhance central cholinergic function may be useful as cognitive enhancers in schizophrenia...
  4. ncbi Potential noradrenergic targets for cognitive enhancement in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    CNS Spectr 9:350-5. 2004
    ....
  5. ncbi Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 159:1388-94. 2002
    ..While cognitive impairment has proven to be a major predictor of overall functional deficit in schizophrenia, other potential factors, such as medical comorbidity, need to be considered...
  6. ncbi A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychopharmacol 28:59-63. 2008
    ....
  7. ncbi Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients
    Joseph I Friedman
    Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:1024-32. 2008
    ....
  8. ncbi The effects of hypertension and body mass index on cognition in schizophrenia
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 167:1232-9. 2010
    ..The authors investigated whether vascular risk factors influence the cognitive impairments of schizophrenia and whether their effects on cognition in schizophrenia are different from those observed in nonpsychiatric comparison subjects...
  9. ncbi Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging
    J I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Am J Psychiatry 158:1441-8. 2001
    ..The rate of decline was compared to changes associated with Alzheimer's disease...
  10. ncbi The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychopharmacol 25:237-42. 2005
    ..Further research on alternative serotonergic approaches to cognitive enhancement in schizophrenia is warranted...
  11. ncbi Guanfacine treatment of cognitive impairment in schizophrenia
    J I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neuropsychopharmacology 25:402-9. 2001
    ....
  12. ncbi Cognition in schizophrenia
    P D Harvey
    Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Psychiatry Rep 3:423-8. 2001
    ....
  13. ncbi CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy
    J I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Mol Psychiatry 13:261-6. 2008
    ..Our data thus confirm an association of CNTNAP2 to epilepsy outside the Old Order Amish population and suggest that dosage alteration of this gene may lead to a complex phenotype of schizophrenia, epilepsy and cognitive impairment...
  14. ncbi Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia
    David M Carpenter
    Department of Radiology ISL, Box 1234, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Neuroreport 19:1369-72. 2008
    ..The findings suggest that there are white matter tract-specific degenerative mechanisms that may be present at the point of illness onset and may progress throughout the illness...
  15. ncbi A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Biol Psychiatry 51:349-57. 2002
    ..An alternative treatment is the allosterically potentiating ligands, which enhance the activity of (sensitize) nicotinic receptors in the presence of acetylcholine...
  16. ncbi Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas
    Philip D Harvey
    Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY 10029, USA
    J Clin Exp Neuropsychol 24:55-66. 2002
    ..These data suggest that cortical versus subcortical profiles of cognitive performance in schizophrenia are inconsistent across ability areas, and are not likely to be the result of stable structural or functional brain deficits...
  17. ncbi Relationships between white matter metabolite abnormalities, cognitive and social functioning in elderly schizophrenic subjects
    Joseph I Friedman
    Schizophr Res 100:356-8. 2008
  18. ncbi Activation symptoms and discharge in elderly chronic schizophrenic inpatients
    Leonard White
    Mount Sinai School of Medicine, New York, New York, USA
    J Nerv Ment Dis 192:880-3. 2004
    ....
  19. ncbi Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics
    Leonard White
    Clinical Neuroscience Center, Pilgrim Psychiatric Center, West Brentwood, NY 11717, USA
    Schizophr Res 88:127-34. 2006
    ..Although many of these patients experience minimal reduction of psychotic symptoms, there may be beneficial effects of antipsychotic treatments on cognitive functions and functional capacity...
  20. ncbi The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change
    Philip D Harvey
    Mt Sinai School of Medicine, New York, NY 10029, USA
    Am J Geriatr Psychiatry 11:610-9. 2003
    ..Authors sought to use a cognitive assessment instrument validated for assessing low-functioning patients to broaden knowledge about the rate and correlates of functional decline...
  21. ncbi Depressed mood and its functional correlates in institutionalized schizophrenia patients
    Nina Rieckmann
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY, 10029, USA
    Schizophr Res 77:179-87. 2005
    ..To determine the frequency of depressed mood in institutionalized schizophrenia patients and its association with illness-related and functional variables...
  22. ncbi White matter changes in schizophrenia: evidence for myelin-related dysfunction
    Kenneth L Davis
    Department of Psychiatry, Kastor Neurobiology of Aging Laboratories, Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine, New York, NY 10021, USA
    Arch Gen Psychiatry 60:443-56. 2003
    ....
  23. ncbi Special issue: Molecular mechanisms of schizophrenia
    Joseph I Friedman
    Biol Psychiatry 60:527-9. 2006
  24. ncbi Validity and stability of performance-based estimates of premorbid educational functioning in older patients with schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Clin Exp Neuropsychol 28:178-92. 2006
    ..The results of these two studies suggest that word-recognition reading skills are useful screening instruments to estimate premorbid functioning even in deteriorated patients with schizophrenia...

Research Grants4

  1. Pimozide Augmentation of Clozapine in Schizophrenia
    Joseph Friedman; Fiscal Year: 2007
    ..This study will provide sorely needed controlled data on the efficacy and safety of a clozapine combination treatment strategy involving adjunctive antipsychotic agents. ..